期刊文献+

人AFP启动子操控的跨膜型抗CD3单链抗体构建及其在AFP阳性肝癌细胞中特异性表达 被引量:1

Preparation of transmembrane anti-CD3 single chain Fv antibody drived by human AFP promoter and its specific expression in AFP positive liver cancer cells
下载PDF
导出
摘要 目的设计肝癌特异性人甲胎蛋白启动子(hAFPp)操控的跨膜型抗CD3单链抗体(antiCD3scfv),使其仅在AFP阳性(AFP+)肝癌细胞中特异性表达。方法利用分子克隆技术构建pAd-hAFPp-CD3scfv腺病毒载体、pAd-hAFPp-antiCD3scfv穿梭质粒载体,经测序验证其基因序列的正确性。取AFP+人肝癌细胞HepG2、Huh-7及AFP阴性(AFP-)正常人肝细胞HL-7702、人乳腺癌细胞MCF-7,利用双荧光素酶报告基因检测系统鉴定hAFPp的肝癌细胞转录特异性;通过Western blotting、免疫荧光、流式分析检测antiCD3scfv蛋白在细胞的表达、定位及表达效率。结果构建的pAd-hAFPp-CD3scfv腺病毒载体、pAd-hAFPp-antiCD3scfv穿梭质粒载体,经测序后基因序列正确。hAFPp在AFP+的HepG2、Huh-7细胞中转录活性分别为160.86%±26.24%、80.08%±12.64%,而在AFP-细胞中转录活性均<7%(P均<0.05)。在AdCD3scfv感染的细胞中,仅HepG2、Huh-7细胞中检测到antiCD3scfv蛋白表达(36.7 kD),且表达于细胞膜表面,细胞中GFP+antiCD3scfv+细胞群比例>90%,而HL-7702、MCF-7均无条带出现。结论携带antiCD3scfv蛋白基因的腺病毒感染周围细胞后,hAFPp调控antiCD3scfv在肝癌细胞的细胞膜特异性表达,进而可能实现antiCD3scfv分子直接介导免疫杀伤的抗肿瘤效果。 Objective To design a transmembrane anti-CD3 single chain Fv antibody(antiCD3scfv)drived by a liver-specific human alpha-fetoprotein promoter(hAFPp),so that it can only be expressed on AFP positive liver cancer cells.Methods Molecular cloning technique was used to construct the adenoviral vector pAd-hAFPp-CD3scfv and plasmid shuttle vector pAd-hAFPp-antiCD3scfv,and the gene sequence was verified by sequencing.AFP positive hepatoma cells HepG2 and Huh-7,AFP negative human normal liver cells HL-7702 and human mammary carcinoma cells MCF-7 were used to verify the specific activity of hAFPp promoter by dual luciferase assay.Western blotting,flow cytometry,and immunofluorescence analysis were performed to detect the expression,localization and expression efficiency of antiCD3scfv protein in cells.Results The adenoviral vector pAd-hAFPp-CD3scfv and plasmid shuttle vector pAd-hAFPp-antiCD3scfv were successfully constructed,and the gene sequence was correct.The transcriptional activities of hAFPp in HepG2 and Huh-7 cells were 160.86%±26.24%and 80.08%±12.64%,while the transcriptional activities in AFP negative cells were<7%(all P<0.05).In AdCD3scfv-infected cells,antiCD3scfv protein expression was only detected in HepG2 and Huh-7 cells(36.7 kD)and expressed on the cell membrane surface.The proportion of GFP+antiCD3scfv+population in cells was greater than 90%,while no protein product was observed in HL-7702 and MCF-7 cells.Conclusion After adenovirus carrying antiCD3scfv protein genes infect the cells around,hAFP promoter regulates membrane specific expression of hepatoma cells;moreover it is possible to achieve the anti-tumor effect of antiCD3scfv molecules directly mediating immune killing.
作者 祁麟 熊梦裳 林芳珍 卢杨 熊冬生 张砚君 范冬梅 张晴 QI Lin1];XIONG Mengshang;LIN Fangzhen;LU Yang;XIONG Dongsheng;ZHANG Yanjun;FAN Dongmei;ZHANG Qing(Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China)
出处 《山东医药》 CAS 2019年第29期1-4,I0001,共5页 Shandong Medical Journal
基金 国家自然科学基金资助项目(81800189)
关键词 肝癌 肿瘤免疫治疗 抗CD3单链抗体 人甲胎蛋白启动子 liver carcinoma tumor immunotherapy anti-CD3 single chain Fv antibody human alpha-fetoprotein promoter
  • 相关文献

参考文献1

二级参考文献72

  • 1Theise ND. Liver cancer. In: WILD BWSCP, editor. World CancerReport 2014. World Health Organization, 2014: 576-592.
  • 2European Association For The Study Of The Liver; EuropeanOrganisation For Research And Treatment Of Cancer. EASLEORTCclinical practice guidelines: management of hepatocellularcarcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI:10.1016/j.jhep.2011.12.001].
  • 3Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterialchemoembolization: modalities, indication, and patient selection.J Hepatol 2015; 62: 1187-1195 [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010].
  • 4Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, TremosiniS, Ayuso C, Llovet JM, Real MI, Bruix J. Survival of patients withhepatocellular carcinoma treated by transarterial chemoembolisation(TACE) using Drug Eluting Beads. Implications for clinical practiceand trial design. J Hepatol 2012; 56: 1330-1335 [PMID: 22314428DOI: 10.1016/j.jhep.2012.01.008].
  • 5Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N,Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N,Makuuchi M. Superselective transarterial chemoembolizationfor hepatocellular carcinoma. Validation of treatment algorithmproposed by Japanese guidelines. J Hepatol 2012; 56: 886-892[PMID: 22173160 DOI: 10.1016/j.jhep.2011.10.021].
  • 6Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF,de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, PortaC, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, BorbathI, H鋟ssinger D, Giannaris T, Shan M, Moscovici M, Voliotis D,Bruix J. Sorafenib in advanced hepatocellular carcinoma. N EnglJ Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857].
  • 7Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, KudoM, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, QianJ, McKee MD, Ricker JL, Carlson DM, El-Nowiem S. Linifanibversus Sorafenib in patients with advanced hepatocellular carcinoma:results of a randomized phase III trial. J Clin Oncol 2015; 33:172-179 [PMID: 25488963 DOI: 10.1200/jco.2013.54.3298].
  • 8Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, ChungHC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S,Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib versussorafenib in advanced hepatocellular cancer: results of a randomizedphase III trial. J Clin Oncol 2013; 31: 4067-4075 [PMID: 24081937DOI: 10.1200/jco.2012.45.8372].
  • 9Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, VanLaethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, MilesS, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C,Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, HassounZ, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME,Chen Y, Porta C. Tivantinib for second-line treatment of advancedhepatocellular carcinoma: a randomised, placebo-controlled phase2 study. Lancet Oncol 2013; 14: 55-63 [PMID: 23182627 DOI:10.1016/s1470-2045(12)70490-4].
  • 10Lencioni R, Llovet JM, Han G, Tak WY, Yang JY, Leberre MA,Niu W, Nicholson K, Meinhardt G, Bruix J. Sorafenib or placeboin combination with transarterial (TACE) with doxorubicin-elutingbeads (DEBDOX) for intermediate-stage hepatocellular carcinoma(HCC): Phase II, randomized, double-blind SPACE trial. J ClinOncol 2012; 30: LBA154.

共引文献23

同被引文献1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部